Business Wire

Berkeley SkyDeck Introduces New Tracks Ahead of Open Applications for Next Cohort Class

Share

Berkeley SkyDeck, the global hub for entrepreneurship and leading accelerator, today announced that applications are now open for its 15th cohort class, with a final deadline of August 31, 2022. Applications are available here. Batch 15 cohorts can take advantage of new tracks added in the last year, including the Aero-Astro Track, led by advisor Robin Riedel of McKinsey and Company, and the Blockchain/Crypto Track, led by advisor Linda Kreitzman. Berkeley SkyDeck’s Chip Track also named a new advisor, David Horsley of UC Davis. In addition, Berkeley SkyDeck will launch a CivTech Track in the coming year, in partnership with the Center for Security in Politics at UC Berkeley, with former Secretary of Homeland Security Janet Napolitano leading the track as a primary advisor. In addition to these new tracks, SkyDeck will continue to work with startups in industries that have always been an area of focus for venture investors, including consumer, enterprise software, biotech, greentech and more.

Berkeley SkyDeck accepts just over 1.5% of startups that apply and approximately 20 to 25 startups overall for each of its cohorts. Cohort companies receive $200,000 in funding, $750,000 worth of free and discounted resources, and access to SkyDeck’s unsurpassed network of UC Berkeley alumni, faculty, and advisors. Alumni of Berkeley SkyDeck have enjoyed great success in their respective industries, collectively raising more than $1.7 billion in funding. The recently launched Berkeley SkyDeck Europe is currently working with its first group of cohorts, who will present their own Demo Day on October 20, 2022.

“Our mission at Berkeley SkyDeck is to continue the tradition of excellence in entrepreneurship and innovation that makes UC Berkeley one of the top public universities in the world. Expanding our operations in Europe and opening additional tracks for our cohorts are just a couple examples of how we are striving to meet the needs of founders around the world,” said Caroline Winnett, Executive Director. “I am looking forward to seeing what these batch applicants have to offer – and how we can leverage the university’s vast resources to set them up for success.”

Berkeley SkyDeck’s newest tracks reflect trends in growth and investments. Last year, for example, aerospace startups raised $15.4 billion while US semiconductor and chip investment reached $2.6 billion in 2021, nearly doubling in just three years. Civtech is also burgeoning, with the industry’s transaction volume rising to $14 billion total in 2021.

“While Berkeley SkyDeck might be rooted here in Silicon Valley, our reach is global, and we’re excited to see how both homegrown and international startups tackle the issues in their industries across all of our tracks,” said Chon Tang, Founding Partner, Berkeley SkyDeck Fund. “As we evaluate, advise, and potentially invest, we are continually energized by these fresh ideas and new approaches. The SkyDeck Fund is ready and waiting to take these newest cohort companies to the next level.”

In March 2022, Berkeley SkyDeck recently announced the close of the $60 million SkyDeck Fund II, which continues to actively fund companies. The SkyDeck Fund has invested in 160 companies to date, representing a wide range of businesses and industries, from 30 countries around the world. Unlike other VC funds, the SkyDeck Fund shares half of its profits with UC Berkeley, helping to continue the university’s mission of delivering excellence in education.

Berkeley SkyDeck will conduct extensive research on applicants, and will hold interviews between September and October 2022. The six-month program will begin in November 2022, concluding at the end of April 2023. Berkeley SkyDeck will host the cohort’s Demo Day for investors on April 4, 2023.

About Berkeley SkyDeck

Berkeley SkyDeck is a leading accelerator and the global hub for entrepreneurship. As UC Berkeley’s largest and most prominent accelerator, SkyDeck combines hands-on mentorship with the vast resources of its research university. SkyDeck is the only accelerator of its kind that offers the value of a dedicated investment fund alongside the resources and network of a top university. To date, SkyDeck startups have raised more than $1.7 billion in aggregate. Participating startups have access to SkyDeck’s 420 advisors, 70 industry partners, and a network of more than 510,000 UC Berkeley alumni. For more information, see skydeck.berkeley.edu.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Songue PR for Berkeley SkyDeck
skydeck@songuepr.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

HiddenA line styled icon from Orion Icon Library.Eye